Drug Trial Radar · NCT01931566
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Last checked: Nov 20, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3,494
Actual
Start
Aug 1, 2013
Primary completion
Jul 24, 2018
Study completion Sep 6, 2018
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Zinfandel Pharmaceuticals Inc.
- First posted
- Aug 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years, up to 83 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.
Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
PioglitazoneDrug
Pioglitazone SR tablets
Pioglitazone placeboDrug
Pioglitazone placebo-matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian ParticipantsTime frame: Baseline to the end of study (approximately up to 5 years)
- Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian ParticipantsTime frame: Baseline to the end of study (approximately up to 5 years)
Locations
55 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Sun City, Arizona
Site not named
Long Beach, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Delray Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Lady Lake, Florida
Site not named
Lake Worth, Florida
Site not named
Merritt Island, Florida
Site not named
Orlando, Florida
Site not named
Port Orange, Florida
Site not named
St. Petersburg, Florida
Site not named
Weston, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Chicago, Illinois
Site not named
Elk Grove, Illinois
Site not named
Elk Grove Village, Illinois
Site not named
Iowa City, Iowa
Site not named
Farmington Hills, Michigan
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Marlton, New Jersey
Site not named
New York, New York
Site not named
Concord, North Carolina
Site not named
Durham, North Carolina
Site not named
Akron, Ohio
Site not named
Portland, Oregon
Site not named
Charleston, South Carolina
Site not named
Cordova, Tennessee
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Middleton, Wisconsin
Site not named
North Ryde, New South Wales, Australia
Site not named
Southport, Queensland, Australia
Site not named
West Heidelberg, Victoria, Australia
Site not named
Nedlands, Western Australia, Australia
Site not named
Berlin, Germany
Site not named
Stuttgart, Baden-Wurttemberg, Germany
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.